Rockefeller Capital Management
HRTX icon

Rockefeller Capital Management’s Heron Therapeutics HRTX Stock Holding History

Rockefeller Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03K Buy
1,286
+871
+210% +$1.01K ﹤0.01% 4483
2025
Q4 		$539 Buy
415
+354
+580% +$437 ﹤0.01% 4518
2025
Q3 		$77 Buy
+61
New +$97 ﹤0.01% 4378
2022
Q4 		– Sell
-200
Closed – – 4016
2022
Q3 		$0 Sell
200
-1,041
-84% -$4.07K ﹤0.01% 4094
2022
Q2 		$3K Buy
1,241
+1,041
+521% +$4.18K ﹤0.01% 3650
2022
Q1 		$1K Hold
200
– – ﹤0.01% 3738
2021
Q4 		$1K Sell
200
-900
-82% -$9.19K ﹤0.01% 3649
2021
Q3 		$11K Sell
1,100
-110
-9% -$1.34K ﹤0.01% 2849
2021
Q2 		$18K Hold
1,210
– – ﹤0.01% 2529
2021
Q1 		$19K Buy
1,210
+1,010
+505% +$18K ﹤0.01% 2303
2020
Q4 		$4K Hold
200
– – ﹤0.01% 2491
2020
Q3 		$2K Hold
200
– – ﹤0.01% 2413
2020
Q2 		$3K Hold
200
– – ﹤0.01% 2226
2020
Q1 		$2K Buy
+200
New +$3.76K ﹤0.01% 2178

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Rockefeller Capital Management's HRTX Position: Q1 2026 in Review

Rockefeller Capital Management increased its Heron Therapeutics (HRTX) stake by 210% in Q1 2026, buying an estimated $1.01K and bringing the position to 1,286 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #4483.

Rockefeller Capital Management first reported a position in HRTX in Q1 2020 and has held it in 14 quarters since. The position peaked at $19K in Q1 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Rockefeller Capital Management held 1,286 shares of Heron Therapeutics worth $1.03K as of Q1 2026.
  • Rockefeller Capital Management bought 871 Heron Therapeutics shares in Q1 2026, an estimated $1.01K.
  • Heron Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4483 holding.
  • Rockefeller Capital Management first reported a position in Heron Therapeutics in Q1 2020 and has held it in 14 quarters since.
  • Rockefeller Capital Management's Heron Therapeutics position peaked at $19K in Q1 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.